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Background. Mass drug administration (MDA) with praziquantel is the cornerstone of schistosomiasis control in sub-Saharan
Africa. The effectiveness of this strategy is dependent on the continued high efficacy of praziquantel; however, drug efficacy is rarely
monitored using appropriate statistical approaches that can detect early signs of wane.
Methods. We conducted a repeated cross-sectional study, examining children infected with Schistosoma mansoni from 6 schools
in Uganda that had previously received between 1 and 9 rounds of MDA with praziquantel. We collected up to 12 S. mansoni egg
counts from 414 children aged 6–12 years before and 25–27 days after treatment with praziquantel. We estimated individual patient
egg reduction rates (ERRs) using a statistical model to explore the influence of covariates, including the number of prior MDA
rounds.
Results. The average ERR among children within schools that had received 8 or 9 previous rounds of MDA (95% Bayesian cred-
ible interval [BCI], 88.23%–93.64%) was statistically significantly lower than the average in schools that had received 5 rounds (95%
BCI, 96.13%–99.08%) or 1 round (95% BCI, 95.51%–98.96%) of MDA. We estimate that 5.11%, 4.55%, and 16.42% of children from
schools that had received 1, 5, and 8–9 rounds of MDA, respectively, had ERRs below the 90% threshold of optimal praziquantel
efficacy set by the World Health Organization.
Conclusions. The reduced efficacy of praziquantel in schools with a higher exposure to MDA may pose a threat to the effective-
ness of schistosomiasis control programs. We call for the efficacy of anthelmintic drugs used in MDA to be closely monitored.
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Schistosoma mansoni is a parasitic trematode and an etiological
agent of the neglected tropical disease schistosomiasis, which is
estimated to infect >230 million people worldwide [1]. The par-
asite has a complex life cycle involving a snail intermediate host,
with humans becoming infected through skin contact with in-
fectious water sources. Chronic morbidity of intestinal schisto-
somiasis is caused by eggs from adult S. mansoni that become
trapped in tissues. This leads to granuloma formation that can
cause fibrosis and portal hypertension [2]. Conservative esti-
mates of morbidity indicate that S. mansoni infection accounts
for 4.4 million cases of blood in stool and 8.5 million cases of
hepatomegaly in sub-Saharan Africa [3].
Interventions to control schistosomiasis have varied over
time. Early national control programs, such as the Sudanese
Blue Nile Health Project (started in 1979) and the Egyptian na-
tional program (started in 1988), used a combination of chemo-
therapy, snail control, provision of clean water and sanitation,
and infrastructural development [4, 5]. Such multiapproach con-
trol programs are now the exception rather than the rule [6].
Due to the low cost, safety, and high efficacy of praziquantel,
mass drug administration (MDA) has become the mainstay of na-
tional control programs.
MDA began in Uganda in 2003 and 400 000 treatments of
praziquantel were distributed that year, with the support of
the Schistosomiasis Control Initiative [7–9]. This has since ex-
panded to the treatment of approximately 1.5 million children
annually [10], resulting in significant reductions in S. mansoni
prevalence, intensity, and associated morbidity [11, 12]. Simi-
lar successes have been reported in other countries implement-
ing MDA [13]. Spurred by these results, the World Health
Organization (WHO) revised its strategic plan from disease
control to the interruption of transmission in certain African
countries, including Uganda, by 2025 [14].With the exception
of certain islands implementing snail control [15], this ambi-
tious plan remains solely reliant on MDA with praziquantel.
Monitoring the continued efficacy of praziquantel is therefore
paramount.
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In the field, S. mansoni is commonly detected by the presence
of eggs in stool, typically using the Kato-Katz thick smear meth-
od, which is inexpensive and practical in low-resource settings
[16]. Because the test suffers from poor sensitivity, though close
to 100% specificity [16], performing multiple readings improves
the chances of detecting eggs in the stools of infected patients
[17]. Egg counts measured before and after treatment are used
to quantify drug efficacy as the egg reduction rate (ERR). The
WHO has set a tentative ERR threshold of 90% as an indicator
of optimal efficacy [18].
The sample ERR is typically calculated directly from egg count
data by applying a simple formula (see equation 1 in “Methods”
section). This is a population-level approach that is not readily
compatible with individual patient data [19]. Such data are better
analyzed using statistical techniques specifically designed for lon-
gitudinally repeated measures and that permit estimation of ERRs
(and their associated uncertainties) for individual patients [20].
These methods can also be used to estimate distributions of
ERRs from individual patients, which are useful for identifying
poor responses and gradual shifts in anthelmintic efficacy [19,20].
Here we assess the effect of previous rounds of MDA on the
efficacy of praziquantel against S. mansoni infections in primary
schoolchildren in eastern Uganda. We explore whether the
number of previous rounds of MDA is associated with efficacy
of praziquantel, estimated as an ERR. We analyze data from a
repeated cross-sectional study of 6 schools that have received
varying numbers of MDA rounds over a period of 11 years.
We fit a statistical model to data on schistosome egg counts be-
fore and 25–27 days after treatment, estimating praziquantel ef-
ficacy using Bayesian techniques at the levels of individual
patients and schools.
METHODS
Study Site
Fieldwork was conducted in Mayuge and Tororo districts,
Uganda, from May to July 2014 (Figure 1). Six government-
run primary schools were included in the study, 5 from Mayuge
district and 1 from Tororo (Table 1; see Supplementary Mate-
rials for GPS coordinates). None of the schools had piped run-
ning water or a pump, and all sanitation facilities were drop pits.
Approximately 6 months had elapsed between the previous
round of MDA and the present study taking place. The MDA
in Tororo in 2013 was the first MDA in this district and
achieved only 21% coverage. MDA in Mayuge has been ongoing
Figure 1. Maps of study sites. A, Map of Uganda in an East African context with Mayuge and Tororo districts highlighted. B, Location of the schools (triangles) surveyed in
Mayuge district. C, Location of the school (triangle) surveyed in Tororo district.
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since 2003, although MDA did not take place in any schools
during 2008–2009.
Enrollment
At baseline, 769 children were recruited from 6 primary schools.
Children were randomly sampled within the age group 6–12 years
and by sex. Children enrolled in the study were examined from 1
to 3 days before and 1 to 3 days after treatment with duplicate
Kato-Katz slides per stool per day (ie, a maximum of 12 counts
per child, up to 6 pretreatment and 6 posttreatment). Treatment
with praziquantel and albendazole, for soil-transmitted helminths
(STHs), was overseen by a nurse, and children were observed for 1
hour following treatment to check for side effects and to exclude
from the efficacy analysis any children who vomited within an
hour (Figure 2). Children were followed up 25–27 days after
treatment.
Our inclusion criteria for the baseline analysis was that the
children were present for at least 1 day before treatment and
so provided a minimum of 2 Kato-Katz thick smears for diag-
nosis. This gave a sample size of 749 patients. Our inclusion cri-
teria for the efficacy analysis were that the child was (1) present
for at least 1 day before and 1 day after treatment; (2) positive
for S. mansoni at baseline, and (3) successfully treated with pra-
ziquantel and albendazole without vomiting. This gave a sample
size of 414 patients (Figure 2).
Sample Egg Reduction Rate
We calculated the sample ERR using
Sample ERR ¼ 1 mean egg count after treatment
mean egg count before treatment
; ð1Þ
where the mean is calculated at the level of the school using all
egg counts, rather than individual-level averages. We used a
nonparametric percentile block bootstrap method to calculate
confidence intervals (CIs) associated with the sample ERR.
Block bootstrap methods [20] account for correlation among
observations (egg counts) from the same individual by random-
ly sampling (with replacement) blocks of data; here, all of an
Table 1. Sample Estimates of the Prevalence and Intensity of Schistosoma mansoni Infection in Children From 6 Primary Schools in Eastern Uganda
Before Treatment With Praziquantel
School District MDA Exposure Category Recruited, No. Tested at Baseline, No. Positive for S. mansoni, No. (%) Mean EPG (95% CI)
Bwondha Mayuge High (9 rounds) 98 96 87 (90.63) 742 (518–973)
Bugoto Mayuge High (9 rounds) 183 170 144 (84.71) 436 (339–534)
Musubi Mayuge High (8 rounds) 128 127 120 (94.49) 465 (362–600)
Bukoba Mayuge Medium (5 rounds)a 120 118 53 (44.92) 92 (67–128)
Bukagabo Mayuge Medium (5 rounds)a 120 118 57 (48.31) 306 (197–442)
Kocoge Tororo Low (1 round) 120 120 81 (67.50) 347 (245–456)
Total 769 749 542 (72.36) 382 (338–446)
The number of previous rounds of MDA to which the school has been exposed and corresponding MDA exposure categories are shown. Infection intensity is quantified as the arithmetic mean
number of EPG. Confidence intervals are calculated using a block bootstrap approach to account for correlation among egg counts repeatedly measured from the same child.
Abbreviations: CI, confidence interval; EPG, egg per gram of feces; MDA, mass drug administration.
a Estimated from district-level MDA coverage from Ministry of Health.
Figure 2. Flow diagram of patient recruitment and exclusion criteria for egg re-
duction rate analysis after treatment with praziquantel (PZQ) and albendazole
(ALB).
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individual’s egg counts before and after treatment. We also ap-
plied this method to calculate CIs associated with mean egg
counts before and after treatment. Details are given in the Sup-
plementary Methods.
Covariates
The schools were selected to give a variety of different MDA his-
tories: 1 round for Kocoge; an estimated 5 rounds for Bukoba
and Bukogabo; and 8 rounds for Musubi and 9 rounds for Bu-
goto and Bwondha, which we classify as low, medium, and high
previous exposure to MDA, respectively (Table 1). While
school-level MDA records were not available for Bukoba and
Bukagabo, the number of MDA rounds was estimated based
on information from Mayuge district officials and district-
level MDA coverage from the Ugandan Ministry of Health.
The sex and weight of each child were recorded at enrollment.
Egg counts for STHs (Ascaris lumbricoides, Trichuris trichiura,
and hookworm species) were also collected. Weight was catego-
rized as low, <22 kg; medium, 22–26 kg, and high, >26 kg. Age
and height were recorded, but dropped as covariates due to their
correlation with weight. Coinfection with STHs was defined as a
binary variable.
Statistical Analysis
We developed and fitted a statistical model to the S. mansoni
egg count data in a Bayesian framework using an approach out-
lined elsewhere [19, 21] and implemented in R [22] with the
package MCMCglmm [23]. Full mathematical details are
given in Supplementary Methods. Here we give a brief descrip-
tion of the features relevant to the estimation of patient ERRs.
The key distributional assumption of the model is that egg
counts measured from a patient at a specific time (before or
after treatment) are Poisson distributed, with an observation-
level random effect permitting extra-Poisson variation or over-
dispersion [19, 22, 23].
The key systematic component of the model is a log-linear
regression structure that describes the change in egg counts
after treatment, x = 1, compared to before treatment, x = 0, in
a multiplicative fashion such that the accompanying treatment
effect coefficient β quantifies the relative change and the ERR is
given by 1 – exp(βx). Covariates enter the model as fixed effects
interacting with x, allowing ERRs to vary among patients of dif-
ferent sex, weight category, and MDA exposure. Random-
effects coefficients, specific to each patient and school and
also interacting with x, permit ERRs to vary among patients
and among schools sharing the same (fixed effect) covariate val-
ues. The correlation (ρ) between random effects (at individual-
patient or school level) quantifies the association between egg
counts before treatment and the treatment effect. A positive cor-
relation at the individual level corresponds to individuals with
higher-than-average egg counts at baseline tending to have
lower ERRs and vice versa for a negative correlation.
Ethical Considerations
Approvals were granted by the Uganda National Council of Sci-
ence and Technology (MoU sections 1.4, 1.5, 1.6) and the Im-
perial College Research Ethics Committee (EC NO: 03.36. R&D
No: 03/SB/033E). Verbal assent was given by every child before
inclusion into this study and at school committee meetings
comprising of parents, teachers, and community leaders before
the onset of the study. Written consent for the children to par-
ticipate in the study was attained from each head teacher. Par-
ticipation was voluntary and children could withdraw or be
withdrawn from the study at any time. All enrolled children
were treated with 40 mg/kg praziquantel and 400 mg albenda-
zole after examination at baseline, and any children who re-
mained positive at follow-up were re-treated.
RESULTS
Summary Epidemiological Statistics
Baseline epidemiological data for each of the 6 schools are
shown in Table 1. The analysis was performed on 749 children
who were present for at least 1 day of sampling before treatment.
The prevalence of S. mansoni at baseline in the schools surveyed
ranged from 44.92% in Bukoba to 94.49% in Musubi. The
Table 2. Estimated Coefficient Posterior Distributions of the Generalized Linear Mixed Model Fitted to Schistosoma mansoni Egg Counts Collected From
414 Children From 6 Primary Schools in Eastern Uganda Before and After Treatment With Praziquantel
Covariate Category Coefficient Posterior Mean (95% BCI) Exponent Coefficient Posterior Mean (95% BCI) Bayesian P Value
Intercept NA 2.32 (1.36 to 3.25) 10.79 (2.17–21.19) .01
Treatment NA −5.65 (−6.81 to −4.55) 3.91 × 10−3 (5.82 × 10−4 to 8.86 × 10−3) <.01
MDA exposure Low (1 round) −1.33 (−3.20 to 0.48) 0.328 (3.36 × 10−9 to 1.03) .10
Medium (5 rounds) −1.42 (−2.94 to 0.25) 0.293 (9.34 × 10−13 to 0.793) .06
Weight Low (<22 kg) 1.21 (0.40–2.03) 3.57 (1.12–6.72) <.01
Medium (22–26 kg) 0.83 (0.01–1.65) 2.45 (0.845–4.74) .05
Sex Male 0.13 (−0.48 to 0.78) 1.19 (5.32–1.98) .67
Coinfection with STH Positive 0.27 (−0.40 to 0.99) 1.37 (0.569–2.43) .44
The posteriors are summarized by their mean and 95% BCI. The coefficient estimates all interact with treatment and thus correspond to the effect of the covariate on the egg reduction rate
(ERR). Negative coefficients (or their exponent <1) associated with covariate–treatment interactions indicate a lower egg count after treatment and a higher ERR and vice versa for positive
coefficients (or their exponent >1) (see “Methods” section).
Abbreviations: BCI, Bayesian credible interval; MDA, mass drug administration; NA, not applicable; STH, soil-transmitted helminth.
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arithmetic mean eggs per gram (EPG) was calculated by averag-
ing over egg counts from schools and multiplying by a factor of
24, rather than from the fitted model, to be comparable with
previous studies in Uganda [24]. The intensity of infection var-
ied 7-fold among schools, from 92 EPG (95% CI, 67–128 EPG)
in Bukoba to 742 EPG (95% CI, 518–973 EPG) in Bwondha.
Of the 414 children included in the praziquantel efficacy
analysis (Figure 2), 209 (50.48%) were female, and the age
range was 6–12 years (median, of 8.5 years). There were no sig-
nificant differences in the fixed-effect characteristics of included
and excluded children (see Supplementary Materials). A total of
4102 egg counts (approximately 10 per child) were collected
from Kato-Katz smears: 2090 before treatment and 2012 after
treatment. Coinfections of S. mansoni and STHs were present
in 141 patients (34.06%), of which the majority were hookworm
(139 [33.57%]).
Figure 3. Estimated egg reduction rates of Schistosoma mansoni from 414 children in eastern Uganda treated with praziquantel. Individual estimates are stratified by school
(A) and by mass drug administration (MDA) exposure category (B). Black points indicate the mean of the posterior distribution, and the gray bars indicate 95% Bayesian credible
intervals (BCIs). The hashed lines correspond to the nominal reference threshold of 90% suggested by the World Health Organization. Note that the BCIs have been truncated at
1% and 99%. Category of MDA reflects the previous number of rounds of treatment with praziquantel the schools have received (high is 8 or 9; medium is 5; low is 1).
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Variation in Praziquantel Efficacy Among Children
The estimated posterior distributions of the model coefficients
associated with praziquantel efficacy are summarized in Table 2
as means and 95% Bayesian credible intervals (BCIs). We also
present the (Bayesian) P values [25] associated with each poste-
rior distribution. Negative coefficients (or their exponent <1)
associated with covariate–treatment interactions indicate a
lower egg count after treatment and a higher ERR and vice
versa for positive coefficients (or their exponent >1). Because
the model is specified at the level of the individual patient, co-
efficients are interpreted as reflecting the fixed covariate effect
on a typical child (ie, when the random-effects adjustments
are equal to 0) [21].
The negative coefficients associated with egg counts mea-
sured after treatment from different low (β = −1.32, P = .10)
and medium (β =−1.42, P = .060) MDA exposure categories in-
dicate that a typical child within a school that has received fewer
previous MDA rounds has a higher ERR than a typical child in a
school that has received more previous rounds of MDA, al-
though these effects are not statistically significant. The positive
coefficients associated with medium (β = .83, P = .0024) and low
(β = 1.21, P = .048) weight categories indicate that a typical child
in these weight categories has a lower ERR than a typical child in
the high weight category. The coefficients of other covariates fit-
ted as interaction terms in the model (sex and coinfection with
STH) are not statistically significantly different from zero. The es-
timated negative correlation between children’s egg counts before
treatment and the treatment effect (ρ =−0.17; see Supplementary
Methods) indicates that children with higher egg counts at base-
line tend to have higher ERRs, albeit the effect is of only marginal
statistical significance (95% BCI, −0.32 to −0.019).
Individual children’s ERRs are variable within each school
and MDA exposure category; however, in the high MDA expo-
sure category, 16.42% (95% BCI, 13.42%–19.78%) of the poste-
rior mean individual ERRs are below the 90% reference efficacy
[18] compared with 4.55% (95% BCI, 1.22%–9.76%) and 5.11%
(95% BCI, 0.00%–10.94%) in the medium and low categories,
respectively (Figure 3). The BCIs quantify the considerable un-
certainty in the individual mean ERR estimates and reflect both
the variation among egg counts measured from the same child
and the number of counts measured per child, which ranged
from 4 to 12. The estimated ERRs and associated 95% BCIs
for each child, stratified by school and MDA exposure category,
are shown in Figure 3.
Variation in the Efficacy of Praziquantel Among Schools
We marginalized (averaged) over the posterior distributions of
the fixed- and random-effects coefficients to yield average ERRs
by schools and MDA exposure categories. Average ERRs are
generally high and ≥90%; however, we find that schools within
the high MDA exposure category show a significantly lower
ERR (91.49% [95% BCI, 88.23%–93.64%]) compared with
both the medium (98.04% [95% BCI, 96.13%–99.08%]) and
low (97.81% [95% BCI, 95.5%–98.96%]) categories, having ad-
justed for other covariate fixed effects (Table 3). For compar-
ison with the model-derived estimates and for comparability
with previous studies, we also calculated sample estimated
ERRs. The sample estimated ERRs follow the same pattern
as the model-derived ERR estimates, with more intensively
treated schools showing lower ERRs, and fall within the corre-
sponding 95% BCI (Table 3). Resampling from the dataset
using fewer egg count readings suggests that 3 days of duplicate
Kato-Katz readings before and after treatment were necessary
to detect the differences in anthelmintic efficacy we observe
between MDA exposure categories (see Supplementary
Materials).
The posterior distributions of average ERRs by school and
MDA exposure category are shown in Figure 4. The distribution
associated with the high MDA exposure category is separated
from the distribution of the medium and low categories, in
Table 3. Estimated Average Egg Reduction Rates of Schistosoma mansoni in 414 Children From 6 Primary Schools in Eastern Uganda Following Treatment
With Praziquantel
MDA Exposure
Category No.
Cleared, No.
(%)
ERR, %
School No.
Cleared, No.
(%)
ERR, %
Sample (95% CI) Model (95% BCI) Sample (95% CI) Model (95% BCI)
High (8–9 rounds) 268 151 (56.34) 92.10 (87.42–95.71) 91.49 (88.23–93.64) Bwondha 68 40 (58.82) 94.27 (88.13–98.26) 94.19 (90.65–96.34)
Bugoto 103 62 (60.19) 89.63 (77.65–96.65) 91.20 (85.40–94.50)
Musubi 97 49 (50.51) 91.98 (82.35–97.69) 89.90 (83.53–93.49)
Medium (5 rounds)a 82 68 (82.93) 98.71 (97.50–99.53) 98.04 (96.13–99.08) Bukoba 42 37 (88.10) 98.98 (97.55–99.85) 98.50 (96.26–99.52)
Bukagabo 40 31 (77.50) 98.58 (96.50–99.64) 97.56 (94.59–99.01)
Low (1 round) 64 45 (70.31) 98.87 (98.07–99.60) 97.81 (95.51–98.96) Kocoge 64 45 (70.31) 98.87 (98.07–99.60) 97.81 (95.51–98.96)
Sample estimates are calculated using equation 1 in “Methods” section, sample egg reduction rates, with 95% confidence intervals (CIs) calculated using a block bootstrap approach to account
for correlation among egg counts repeatedly measured from the same child. Model estimates and 95% BCIs correspond to the posterior distribution of the average ERR by mass drug
administration (MDA) exposure category and by school calculated by marginalizing (averaging) over the appropriate fixed- and random-effects coefficients of the fitted generalized linear
mixed model.
Abbreviations: BCI, Bayesian credible interval; ERR, egg reduction rate.
a Estimated from district-level MDA coverage from the Ministry of Health.
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accordance with a lower average efficacy of praziquantel for
children in schools with a higher past exposure to MDA.
DISCUSSION
We have tested the impact of a school’s past exposure to MDA
with praziquantel on present treatment outcomes for S. manso-
ni. We have demonstrated through the use of an appropriate
statistical modeling technique that treatment efficacy, as quan-
tified by the ERR, is lower in schools that have been treated in 8
or 9 previous MDA rounds compared with other schools from
the same or nearby districts that have undergone ≤5 rounds of
MDA with praziquantel.
From the baseline data we collected from the schools (Table 1),
we found a high prevalence (>84%) and infection intensity
Figure 4. Posterior distribution of average egg reduction rates (ERRs) of Schistosoma mansoni in 414 children from 6 primary schools in eastern Uganda treated with pra-
ziquantel. The average ERRs are stratified by school (A) and by mass drug administration (MDA) exposure category (B). The posteriors were constructed by marginalizing over the
fixed- and random-effects coefficients estimated from the generalized linear mixed model. The colored hashed lines indicate the mean of the posterior. Category of MDA
reflects the previous number of rounds with praziquantel the schools have received (high is 8 or 9; medium is 5; low is 1).
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(>400 EPG) in Bugoto, Bwondha, and Musubi, the schools that
have undergone the highest number of previous MDA rounds. It
is surprising that S. mansoni infection remains entrenched within
these foci despite up to 9 rounds of MDA. We concur that per-
sistence of the parasite population is driven by continued reinfec-
tion from transmission hotspots in Lake Victoria [26]. It is
concerning for efforts to halt transmission of S. mansoni through
MDA alone that areas with high infection intensity are so resil-
ient to repeated treatments.
We found that the weight of children was associated with es-
timated ERRs. The dose of praziquantel is weight-standardized
at 40 mg/kg and hence one would not expect differences in drug
efficacy among children of different weight. The lower ERR in
lighter children suggests that they are not receiving a sufficient
dose, perhaps indicating that there is a minimum therapeutic
dose that lighter children are failing to receive. There could
also be an age-dependent effect (as weight and age are closely
correlated) reflecting synergism between the development of
protective immune responses and the antischistosomal activity
of praziquantel [27].
A recent meta-analysis of praziquantel efficacy reported an
average ERR of 89.1% (95% CI, 83.3%–94.2%) among treated
S. mansoni infections in schoolchildren, with a median fol-
low-up time of 5 weeks [28]. The comparable estimates of the
ERR in this study are the average school-level estimates, includ-
ing those for different MDA exposure categories. None of our
estimates extend below the lower CI of the meta-review esti-
mates, suggesting that praziquantel remains broadly efficacious
in all our study sites (although heterogeneity in study design
will naturally widen CIs estimates from a meta-analysis com-
pared to estimates obtained from a single study). However, of
concern is the significant difference in estimated ERRs we ob-
serve between schools that have received more previous rounds
of MDA compared with those that have received fewer rounds
(Table 3 and Figure 4).
Variation in anthelmintic efficacy is driven by parasite- and
host-specific factors. Without long-term longitudinal data (ie,
on the scale of years, over multiple rounds of MDA), or baseline
data from before MDA commenced, we cannot determine
whether heterogeneities among ERRs, at either the individual
or school level, are static or changing temporally. A systematic de-
cline in ERRs could be indicative of increasing parasite tolerance
or emerging resistance to praziquantel [29, 30]. Intervention pro-
grams usingMDA should incorporate regular assessment of drug
efficacy into their monitoring and evaluation protocols.
A recent analysis of praziquantel efficacy against S. mansoni
found variation among ERRs from individual patients to be
greater in Uganda than in other countries [21]. Schistosoma
mansoni parasites in Uganda have been observed to be more ge-
netically diverse than elsewhere [31], which could be driving
more variable treatment outcomes. Host factors such as genetic
variation or differences in nutritional status are unlikely to be
sufficient to explain the variation in ERRs because of the spatial
proximity and similar patterns of subsistence in the schools sur-
veyed (Figure 1). It is also unlikely that different rates of reinfec-
tion are driving substantive differences among patient ERRs.
This is because the time to follow-up (25–27 days) is short
and the statistical model is designed to control for different
rates of reinfection by modeling the intensity of infection
after treatment relative to the intensity before treatment such
that each individual acts as its own control.
We are left with the possible explanation that reduced prazi-
quantel efficacy is caused by drug-tolerant genetic variants
within the S. mansoni population in highly treated areas. Genet-
ic changes associated with drug resistance have been associated
with drug-induced selection pressures in human and veterinary
helminthiases [32–35]. Ultimately, drug-induced resistance can
only be confirmed by linking changes in resistance allele fre-
quencies to phenotypic indicators of drug tolerance or reduced
susceptibility. As neither the precise mode of action of prazi-
quantel nor the genetic basis of resistance in schistosomes is
completely understood [36], the powerful approaches offered
by next-generation sequencing will be essential to scan for selec-
tion across whole genomes [37, 38]. Such approaches would
help to establish if parasite genetic variation could be driving
the degree of variation in praziquantel efficacy that we have ob-
served in this study.
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